HilleVax announced a workforce reduction to reduce its operating expenses. The reduction of approximately 41 employees, or approximately 40% of the company’s workforce, is intended to preserve cash while maintaining core capabilities as the company explores the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates as well as business development-related activities for these vaccine candidates.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HLVX:
- HilleVax, Inc. Clears $26.2M Debt and Ends Loan Agreement
- HilleVax downgraded to Market Perform from Outperform at Leerink
- Tempus AI initiated, Helios downgraded: Wall Street’s top analyst calls
- HilleVax downgraded to Neutral from Buy at H.C. Wainwright
- HilleVax downgraded to Hold from Buy at Stifel